Clinical aspects of invasive candidiasis in paediatric patients

Area of Science:

• Medical Mycology
• Paediatric Infectious Diseases
• Immunology

Background:

• Candida infections present a critical health concern in pediatric populations, leading to substantial mortality rates.
• Neonates and children with congenital immunodeficiencies are particularly vulnerable to severe outcomes from invasive candidiasis.
• Current understanding of specific risk factors for invasive candidiasis in these vulnerable pediatric groups remains limited.

Purpose of the Study:

• To elucidate the factors contributing to an increased risk of invasive candidiasis in newborns.
• To identify risk factors associated with invasive candidiasis in pediatric patients with congenital immunodeficiencies.
• To review current treatment strategies for invasive candidiasis in pediatric patients.

Main Methods:

• Review of existing studies characterizing risk factors for invasive candidiasis in neonates.
• Analysis of studies focusing on risk factors in pediatric patients with various congenital immunodeficiencies.
• Evaluation of current treatment guidelines and recommendations for invasive candidiasis in pediatric populations.

Main Results:

• Neonatal invasive candidiasis risk is primarily linked to colonization.
• Risk factors for invasive candidiasis in immunocompromised children vary based on the specific immunodeficiency.
• Fluconazole is identified as a suitable treatment option for invasive candidiasis in pediatric patients.

Conclusions:

• Understanding specific risk factors is crucial for preventing invasive candidiasis in vulnerable pediatric populations.
• Tailoring risk assessment based on age (neonates) and specific immune status (congenital immunodeficiencies) is essential.
• Treatment strategies for pediatric invasive candidiasis should align with established adult protocols, with fluconazole being a recommended agent.